强迫症患者加用喹硫平：治疗结果是否受5-羟色胺再摄取抑制剂类型和剂量的影响？
Quetiapine addition in obsessive-compulsive disorder: is treatment outcome affected by type and dose of serotonin reuptake inhibitors?
作者信息
Denys Damiaan, Fineberg Naomi, Carey Paul D, Stein Dan J
机构信息
The Rudolf Magnus Institute of Neuroscience, Department of Psychiatry, University Medical Center Utrecht, Utrecht, The Netherlands.
出版信息
Biol Psychiatry. 2007 Feb 1;61(3):412-4. doi: 10.1016/j.biopsych.2006.12.014.
BACKGROUND
The purpose of this study was to assess the effect of type and dose of serotonin reuptake inhibitors (SRIs) on treatment outcome in quetiapine addition trials for obsessive-compulsive disorder.
METHODS
Results from all available, double blind, placebo-controlled quetiapine addition trials were pooled. Treatment outcome was assessed in a sample of 102 patients by change from baseline to end point on the Yale-Brown obsessive-compulsive scale (Y-BOCS).
RESULTS
Quetiapine addition was superior with a mean Y-BOCS decrease of 6.8 +/- 6.7 compared with placebo with a decrease of 3.9 +/- 6.5 points. Patients with the lowest SRI dose showed the largest decrease on the Y-BOCS (11.6 +/- 7.7) compared with patients with the median dose (6.1 +/- 6.1) and highest dose (5.9 +/- 6.4).
CONCLUSIONS
We found a superior response in the quetiapine addition group compared with the placebo group. The best response was achieved with the combination of clomipramine, fluoxetine, and fluvoxamine and with the lowest SRI doses.
背景
本研究旨在评估5-羟色胺再摄取抑制剂（SRIs）的类型和剂量对强迫症患者喹硫平添加试验治疗结果的影响。
方法
汇总所有可得的双盲、安慰剂对照的喹硫平添加试验结果。通过102例患者样本从基线到终点的耶鲁-布朗强迫症量表（Y-BOCS）变化来评估治疗结果。
结果
添加喹硫平组效果更佳，Y-BOCS平均降低6.8±6.7，而安慰剂组降低3.9±6.5分。与接受中等剂量（6.1±6.1）和高剂量（5.9±6.4）的患者相比，接受最低SRI剂量的患者Y-BOCS降低幅度最大（11.6±7.7）。
结论
我们发现添加喹硫平组比安慰剂组反应更佳。氯米帕明、氟西汀和氟伏沙明联合使用且SRI剂量最低时疗效最佳。
Zotero 插件